The Immunotherapy Foundation icon, an "if" inside a circle A blue and green "stop" X A DNA symbol in a ring An injection in a ring A pill in a ring A green and blue broken chain link A location icon A dark location icon A telephone icon A dark phone icon An email/letter icon A dark mail icon Facebook icon Facebook icon Twitter icon Twitter icon Instagram icon Instagram icon A hamburger menu A closing X icon A simple caret A systemic icon Bullseye A clock Reduced side-effects Resistance

Making Progress, Every Day.

Keep up with the latest trials and treatments

News & Updates Patient Resources Go T Cells Go!

All Trials & Treatments

Vaginal Cancer

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors

Trial Identifier: NCT03192345
Phase: 1
Sponsors: Sanofi
Date: Last updated 4/13/2018
Regions: US; South; Investigational Site Number 8400006, Nashville, TN 37203; Investigational Site Number 8400003, Dallas, TX, 75230
Contact: For site information, send an email with site number to Contact-Us@sanofi.com

To determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of SAR439459 when administered intravenously as monotherapy in adult patients with advanced solid tumors, et al.


A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

Trial Identifier: NCT03248843
Phase: 1
Sponsors: 3D Medicines (Sichuan) Co., Ltd.
Date: Last updated 1/18/2018
Regions: Asia; Japan; St. Marianna University School of Medicine Hospital Recruiting, Kawasaki, 216-8511; National Cancer Center Hospital, Tokyo, 104-0045
Contact: Kawasaki: Takako Nakajima, MD, tnakajima@marianna-u.ac.jp, 044-977-8111; Tokyo: Toshio Shimizu, MD, tosshimi@ncc.go.jp, +81 3-354-2511 ext 7003

This is an open label, dose escalation study to evaluate the safety and tolerability of KN035 in Japanese patients with advanced and metastatic solid tumor. The dose escalation will follow the widely used 3+3 design.


Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001)

Trial Identifier: NCT03249792
Phase: 1
Sponsors: Merck Sharp & Dohme Corp.
Date: Last updated 4/24/2018
Regions: Multi-region; US; Northeast and Mid-Atlantic; US; South; US; West Coast; US; Midwest; University of California San Diego Moores Cancer Center (Site 0004) La Jolla, CA 92093; UCLA Medical Center (Site 0003) Los Angeles, CA 90095; University of Chicago (Site 0002) Chicago, IL 60637; New York Presbyterian Hospital/Columbia University (Site 0001) New York, NY 10032; Mary Crowley Cancer Research Center (Site 0005) Dallas, TX 75246
Contact: Moores Cancer Center (Site 0004) Study Coordinator 858-822-6477; UCLA Medial Center (Site 0003) Study Coordinator 310-582-4048; University of Chicago (Site 0002) Study Coordinator 773-834-3096; New York Presbyterian Hospital/Columbia University (Site 0001) Study Coordinator 212-305-3997; Mary Crowley Cancer Research Center (Site 0005) Study Coordinator 214-658-1965

The purposes of this study are to: 1) assess the safety and tolerability and 2) establish a preliminary recommended Phase 2 dose (RP2D) and/or a maximum tolerated dose (MTD) or a maximum administered dose (MAD) of MK-2118 when administered via intratumoral (IT) injection as monotherapy and in combination with pembrolizumab (MK-3475) intravenous (IV) infusion.


The Study of SHR7390 in Combination With SHR-1210 in Patients With Advanced Solid Tumors

Trial Identifier: NCT03182673
Phase: 1
Sponsors: Jiangsu HengRui Medicine Co., Ltd.
Date: Last updated 2/28/2018
Regions: Asia, China, The Cancer Center, Sun Yat-sen University Guangzhou, Guangdong, 510060
Contact: RuiHua Xu, MD, PhD 86-20-8734-3008 xurh@sysucc.org.cn or Yi Liu, PhD 86-21-6045-3192 ext 822 liuy@shhrp.com.

This aim of study to assess the safety and tolerability of SHR7390 combined with SHR-1210 and to define Dose limiting toxicity(DLT)and the maximum tolerated dose (MTD) of SHR7390 in the patients with advanced solid tumors.


Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)

Trial Identifier: NCT03179436
Phase: 1
Sponsors: Merck Sharp & Dohme Corp.
Date: Last updated 5/28/2018
Regions: Middle East; Israel; US; South; Texas Accelerated Research Therapeutics, LLC (START) (Site 0001), San Antonio, TX, 78229; Israel Rambam Medical Center (Site 0003) Haifa, Israel; Sheba Medical Center - Cancer Center ( Site 0002) Ramat-Gan, Israel
Contact: Site 0001 Study Coordinator: 210-593-5250; Site 0002 Study Coordinator: +97235307096; Site 0003 Study Coordinator: +97235307096; General: 1-888-577-8839, Trialsites@merck.com

This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of MK-1308 when used in combination with pembrolizumab in participants with advanced solid tumors.


Special Combination of OBP-301 and Pembrolizumab

Trial Identifier: NCT03172819
Phase: 1
Sponsors: Toshihiko Doi, National Cancer Center Hospital East; Oncolys BioPharma Inc, Merck Sharp & Dohme Corp.
Date: Last updated 10/19/2017
Regions: Asia; Japan; National Cancer Center Hospital East; Kashiwa, Chiba
Contact: Takashi Kojima, Dr +81-4-7133-1111 ext 91266, OBPem_core@east.ncc.go.jp

This is multicenter, open-label Phase I study to exploratively evaluate the efficacy and safety of OBP-301 in combination with Pembrolizumab in patients with advanced solid tumors.


Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Trial Identifier: NCT03172936
Phase: 1
Sponsors: Novartis
Date: Last updated 1/4/2018
Regions: Multi-region; refer to contact details.
Contact: 1-888-669-6682, Novartis.email@novartis.com. Please refer to this study by its ClinicalTrials.gov identifier.

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.


Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Trial Identifier: NCT02834013
Phase: 2
Sponsors: National Cancer Institute (NCI)
Date: Last updated 6/12/2018
Regions: Multi-region; See all 710 study sites here
Contact: Use trial site search for specific contact details.

This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.


Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors

Trial Identifier: NCT03190811
Phase: 1/2
Sponsors: Capital Medical Unviersity, Duke University
Date: Last updated 12/7/2017
Regions: Asia; China; Beijing - Capital Medical University Cancer Center/Beijing Shijitan Hospital Recruiting Beijing, Beijing, 100038
Contact: Jun Ren, MD, PhD 86-10-63926317, renjun9688@yahoo.com

The purpose of this study is to compare the clinical efficacy and toxicity of anti-PD-1 monoclonal antibody alone with anti-PD-1 monoclonal antibody plus autologous dendritic cells-cytokine induced killer cell (DC-CIK) immunotherapy in advanced tumor patients.



Vaginal Cancer (HPV+)

E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers

Trial Identifier: NCT02858310
Phase: 1
Sponsors: National Cancer Institute (NCI)
Date: Last updated 6/8/2018
Regions: US; Northeast and Mid-Atlantic; National Institutes of Health Clinical Center, Bethesda, MD
Contact: Erin W Ferraro, R.N. (240) 760-6163, erin.ferraro@nih.gov

Researchers will take a person's blood, remove certain white blood cells, and insert genes that make them to target cancer cells that have the E7 protein unique to HPV cancers. The genetically changed cells, called E7 TCR cells, are then given back to the person to fight the cancer. Objective: To determine a safe dose of E7 TCR cells and whether these cells can help patients.


An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (CheckMate358)

Trial Identifier: NCT02488759
Phase: 1/2
Sponsors: Bristol-Myers Squibb
Date: Last updated 5/22/2018
Regions: Multi-region; Recruiting sites have contact information.
Contact: Please contact the sites directly: clinical.trials@bms.com; First line of the email MUST contain NCT# and Site #.

The purpose of this study to investigate the safety and effectiveness of Nivolumab, and Nivolumab combination therapy, to treat patients who have virus-associated tumors.


HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers, HESTIA

Trial Identifier: NCT02379520
Phase: 1
Sponsors: Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine The Methodist Hospital System
Date: Last updated 4/25/2018
Regions: US; South; Houston Methodist Hospital, Houston, TX
Contact: Carlos A. Ramos, MD 832-824-4817, caramos@bcm.edu or Vicky Torrano 832-824-7821, vtorrano@bcm.edu

The purpose of this study is to find the biggest dose of HPVSTs (special immune system cells) that is safe, to see how long they last in the body, to learn what the side effects are and to see if the HPVSTs will help people with HPV-associated cancers. (Click trial identifier to read more.)

 

Patient Diagram